Clinical trial · no report yet · Phase 2
NCT07229417
A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma
- NCT07229417 ↗
- Recruiting
- M.D. Anderson Cancer Center
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 2 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Metastatic Endocrine Refractory; Triple Negative Invasive Lobular Carcinoma
- Interventions
- Ivonescimab
- Arms
- Phase II: Treatment with Ivonescimab · Experimental
- Enrollment
- 29 (estimated)
- Primary outcomes
- Safety and adverse events (AEs)
- Sponsor
- M.D. Anderson Cancer Center
- Start
- Oct 22, 2025
- Primary completion
- Sep 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT07229417 · updated Jul 29, 2026